

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of December 2018

	31.12.2018	31.12.2017
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	25 166	26 803
Intangible assets	2 871	2 998
Investment in minority interest	1	1
Trade receivables	6 853	5 960
Total non-current assets	34 891	35 762
Current assets		
Inventories	5 491	5 190
Trade and other receivables	69 775	55 998
Treasury shares redeemed	92	8
Current corporate income tax	4	
Cash and cash equivalents	250	24
Total current assets	75 612	61 220
Total assets	110 503	96 982
LIABILITIES		
Equity		
Share capital	72 200	64 300
Reserves	10 084	9 172
Retained earnings	11 352	8 831
Total	93 636	82 303
Non-current liabilities		
Long-term loans	324	590
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	119	83
Total non-current liabilities	1 751	1 981
Current liabilities		
Trade and other liabilities	4 195	2 134
Short-term loans	9 777	9 784
Current portion of long-term loans	265	491
Current corporate income tax		78
Other tax liabilities	879	211
Total current liabilities	15 116	12 698
Total liabilities	16 867	14 679
Total equity and liabilities	110 503	96 982

Date of preparation: 25.01.2019

Sofia

Prepared by:.....

/ P. Moneva /



Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of December 2018

	31.12.2018	31.12.2017
	BGN'000	BGN'000
Revenue	38 464	33 359
Other income	46	76
Total income	38 510	33 435
Carrying amount of goods sold	(2 326)	(1 719)
Changes in inventories of finished products and work in progress	(118)	432
Materials and services	(13 605)	(13 726)
Personnel expenses	(3 890)	(3 544)
Depreciation / amortisation expenses	(3 272)	(3 084)
Other expenses	(2 406)	(1 692)
Finance income	17	88
Finance costs	(438)	(381)
Total expenses	(26 038)	(23 626)
Profit before taxation	12 472	9 809
Corporate income tax expense	(1 120)	(978)
Profit/Loss for the period	11 352	8 831
Total comprehensive income for the period		
Earnings per share / in BGN per 1 share /	0.16	0.14

Date of preparation: 25.01.2019

Sofia

Prepared by:
 / P. Moneva /



Executive Director:
 /B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of December 2018

	31.12.2018	31.12.2017
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	28 229	30 929
Payments to suppliers of materials, goods and services	(13 818)	(15 539)
Payments to personnel	(3 472)	(3 456)
Payments of interest and dividends	(21)	(16)
Corporate income tax payments	(1 291)	(989)
Other proceeds / payments	(7 285)	(5 534)
Net cash flows	2 342	5 395
Cash flows from investing activities		
Payments on non-current assets acquired	(1 399)	(2 757)
Net cash flows	(1 399)	(2 757)
Cash flows from financial activities		
Proceeds from loans	188	172
Payments on loans	(188)	(1 738)
Payment of interest, dividends	(196)	(224)
Payments on finance lease	(527)	(866)
Other proceeds/payments	6	(8)
Net cash flows	(717)	(2 664)
Change in cash and cash equivalents		
Cash and cash equivalents at the beginning of the period	24	50
Cash and cash equivalents at the end of the period	250	24

Date of preparation: 25.01.2019

Sofia

Prepared by:.....

/ P. Moneva /



Executive
Director:.....

/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as 31 of December 2018

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2017	56 600	3 149	4 661	8 585	72 995
Profit/loss for the period				8 831	8 831
Other comprehensive income		477			477
Including from tax effect of the revaluation of property, plant and equipment		(60)			(60)
Total comprehensive income		477		8 831	9 308
Issue of shares by the owners	7 700			(7 700)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			885	(885)	
Total amount of income and expenses recognised during the period	7 700		885	(8 585)	
Balance as of 31.12.2017	64 300	3 626	5 546	8 831	82 303
Balance as of 01.01.2018	64 300	3 626	5 546	8 831	82 303
Profit/loss for the period				11 352	11 352
Other comprehensive income		(19)			(19)
Total comprehensive income		3 607		11 352	11 352
Issue of shares by the owners	7 900			(7 900)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			931	(931)	
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2018	72 200	3 607	6 477	11 352	93 636

Date of preparation: 25.01.2019
Sofia

Prepared by:.....
/P. Moneva/



Executive Director:.....
/B. Georgiev /